206 related articles for article (PubMed ID: 18423013)
21. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers.
Agúndez JA; Olivera M; Ladero JM; Rodriguez-Lescure A; Ledesma MC; Diaz-Rubio M; Meyer UA; Benítez J
Pharmacogenetics; 1996 Dec; 6(6):501-12. PubMed ID: 9014199
[TBL] [Abstract][Full Text] [Related]
22. Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women.
Zgheib NK; Shamseddine AA; Geryess E; Tfayli A; Bazarbachi A; Salem Z; Shamseddine A; Taher A; El-Saghir NS
Mutat Res; 2013; 747-748():40-7. PubMed ID: 23628324
[TBL] [Abstract][Full Text] [Related]
23. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.
An HR; Wu XQ; Wang ZY; Zhang JX; Liang Y
Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):535-43. PubMed ID: 22506592
[TBL] [Abstract][Full Text] [Related]
24. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
[TBL] [Abstract][Full Text] [Related]
25. N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population.
Mishra S; Daschakraborty S; Shukla P; Kapoor P; Aggarwal R
Natl Med J India; 2013; 26(5):260-5. PubMed ID: 25017831
[TBL] [Abstract][Full Text] [Related]
26. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.
Singla N; Gupta D; Birbian N; Singh J
Tuberculosis (Edinb); 2014 May; 94(3):293-8. PubMed ID: 24637014
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
[TBL] [Abstract][Full Text] [Related]
28. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
Nebert DW; McKinnon RA; Puga A
DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
[TBL] [Abstract][Full Text] [Related]
29. Association of genetic polymorphisms of
Yang S; Hwang SJ; Park JY; Chung EK; Lee JI
BMJ Open; 2019 Aug; 9(8):e027940. PubMed ID: 31375612
[TBL] [Abstract][Full Text] [Related]
30. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
Lee SW; Chung LS; Huang HH; Chuang TY; Liou YH; Wu LS
Int J Tuberc Lung Dis; 2010 May; 14(5):622-6. PubMed ID: 20392357
[TBL] [Abstract][Full Text] [Related]
31. Inter-ethnic differences in genetic polymorphisms of xenobiotic-metabolizing enzymes (CYP1A1, CYP2D6, NAT1 and NAT2) in healthy populations: correlation with the functional in silico prediction.
Khlifi R; Ben Salah G; Chakroun A; Hamza-Chaffai A; Rebai A
Mol Biol Rep; 2014 Sep; 41(9):5735-43. PubMed ID: 24934312
[TBL] [Abstract][Full Text] [Related]
32. Genetic variation of genes for xenobiotic-metabolizing enzymes and risk of bronchial asthma: the importance of gene-gene and gene-environment interactions for disease susceptibility.
Polonikov AV; Ivanov VP; Solodilova MA
J Hum Genet; 2009 Aug; 54(8):440-9. PubMed ID: 19575027
[TBL] [Abstract][Full Text] [Related]
33. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis.
Bose PD; Sarma MP; Medhi S; Das BC; Husain SA; Kar P
J Gastroenterol Hepatol; 2011 Feb; 26(2):312-8. PubMed ID: 21261721
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome P450 (CYP450,2D6*A), N-Acetyltransferase-2 (NAT2*7, A) and Multidrug Resistance 1 (MDR1 3435 T) Alleles Collectively Increase Risk of Ulcerative Colitis.
Lotfi F; Bahrehmand F; Vaisi-Raygani A; Khodarahmi R; Tanhapour M; Kiani A; Rahimi Z; Pourmotabbed T
Arch Iran Med; 2018 Nov; 21(11):530-535. PubMed ID: 30551694
[TBL] [Abstract][Full Text] [Related]
35. Influence of GSTT1, mEH, CYP2E1 and RAD51 polymorphisms on diepoxybutane-induced SCE frequency in cultured human lymphocytes.
Schlade-Bartusiak K; Rozik K; Laczmanska I; Ramsey D; Sasiadek M
Mutat Res; 2004 Mar; 558(1-2):121-30. PubMed ID: 15036125
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms in the human cytochrome P450 and arylamine N-acetyltransferase: susceptibility to head and neck cancers.
Khlifi R; Messaoud O; Rebai A; Hamza-Chaffai A
Biomed Res Int; 2013; 2013():582768. PubMed ID: 24151610
[TBL] [Abstract][Full Text] [Related]
37. Significance of the genetic polymorphism of CYP2D6 and NAT2 in patients with inflammatory bowel diseases.
Dudarewicz M; Rychlik-Sych M; Barańska M; Wojtczak A; Trzciński R; Dziki A; Skrętkowicz J
Pharmacol Rep; 2014 Aug; 66(4):686-90. PubMed ID: 24948072
[TBL] [Abstract][Full Text] [Related]
38. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population.
Guaoua S; Ratbi I; Laarabi FZ; Elalaoui SC; Jaouad IC; Barkat A; Sefiani A
BMC Genet; 2014 Dec; 15():156. PubMed ID: 25544508
[TBL] [Abstract][Full Text] [Related]
39. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.
Cho HJ; Koh WJ; Ryu YJ; Ki CS; Nam MH; Kim JW; Lee SY
Tuberculosis (Edinb); 2007 Nov; 87(6):551-6. PubMed ID: 17950035
[TBL] [Abstract][Full Text] [Related]
40. Association of Genetic Variants of CYP2C19 and CYP2D6 with Esophageal Squamous Cell Carcinoma Risk in Northern India, Kashmir.
Bhat GA; Bhat AB; Lone MM; Dar NA
Nutr Cancer; 2017; 69(4):585-592. PubMed ID: 28368717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
